METHODS OF ASSOCIATING GENETIC VARIANTS WITH CLINICAL OUTCOME IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTI-VEGF THERAPY
CY1126278T1Undetermined Publication Date: 2026-07-31REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CY20231100607T
- Authority / Receiving Office
- CY · CY
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-02-04
- Filing Date
- 2023-11-01
- Publication Date
- 2026-07-31
- Estimated Expiration
- 2043-11-01
Abstract
Methods for correlating a genetic variant with intraretinal fluid as a marker of response to anti-VEGF therapy in age-related macular degeneration (AMD). Further methods for correlating a genetic variant with visual acuity, anatomical outcomes, or treatment frequency are disclosed herein. The genetic variants identified were found in a non-gene region on the X chromosome p.22.3 in the MICOM gene in the NTRK3 gene and in the ANK2 gene.
Need to check novelty before this filing date? Find Prior Art